Malignant Pleural Mesothelioma: Present Status and Future Directions

Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Imaging Evaluation in Malignant Pleural Mesothelioma

Pp. 213-231 (19)

Beth A. Ripley and Ritu R. Gill

Abstract

Malignant pleural mesothelioma continues to be a challenging tumor to image and treat. A multimodality multidisciplinary team approach including surgery, oncology, radiology and radiation therapy is required for successful outcomes. Reliable and reproducible methods of assessing treatment response are crucial for guiding management, whether for clinical practice, research, or to meet the requirements of a clinical trial. Computed Tomography is the first line imaging modality due to its superb spatial resolution and volumetric data set, allowing for 3D reconstructions that aid in tumor volume assessment and surgical planning. MRI has the potential to provide qualitative, quantitative, anatomical and functional information without the use of ionizing radiation or intravenous contrast administration. Newer advances and optimization of existing protocols can help identify imaging biomarkers that can serve as surrogates of survival.

Keywords:

ADC, DCE-MRI, DWI, Mesothelioma, RECIST, tumor volume.

Affiliation:

Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, 20120 MA, United States.